Clinical and biological effects of mifepristone treatment for psychotic depression

Neuropsychopharmacology

Volumn 31, Issue 3, 2006, Pages 628-636

  Flores, Benjamin H ^a   Kenna, Heather ^a   Keller, Jennifer ^a   Solvason, Hugh Brent ^a   Schatzberg, Alan F ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

ACTH; Cortisol; Glucocorticoid antagonist; Mifepristone; Mineralocorticoid receptor; Psychotic depression

Indexed keywords

CORTICOTROPIN; GLUCOCORTICOID RECEPTOR ANTAGONIST; HYDROCORTISONE; MIFEPRISTONE; PLACEBO;

AGE DISTRIBUTION; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOTROPIN BLOOD LEVEL; DEPRESSIVE PSYCHOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HAMILTON SCALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SYMPTOM;

ADRENOCORTICOTROPIC HORMONE; ADULT; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HORMONE ANTAGONISTS; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LINEAR MODELS; MALE; MIFEPRISTONE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, GLUCOCORTICOID; SEX CHARACTERISTICS;

EID: 33244489555     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300884     Document Type: Article

References (42)

1. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF (2001). Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 21: 516-521.
2. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C et al (2002). An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 52: 386-392.
3. Born J, DeKloet ER, Wenz H, Kern W, Fehm HL (1991). Gluco- and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors. Am J Physiol 260: E183-E188.
4. Coryell W, Pfohl B, Zimmerman M (1984). The clinical and neuroendocrine features of psychotic depression. J Nerv Ment Dis 172: 521-528.
5. De Kloet ER (1991). Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 12: 95-164.
6. DeBattista C, Belanoff J (2004). A double-blind, placebo controlled trial of C-1073 (mifepristone) in the treatment of psychotic major depression. Presented at the 43rd Annual Meeting of the American College of Neuropsychopharmacology, San Juan: Peurto Rico.
7. DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF (2000). Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am J Psychiatry 157: 1334-1337.
8. Fink M, Nemeroff CB (1989). A neuroendocrine view of ECT. Convulsive Ther 5: 296-304.
9. First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM IV-TR Axis I Disorders - Patient Edition (SCID-I/P, 2/2001 revision). American Psychiatric Press, Inc.: Washington, DC.
10. Fleming SK, Blasey C, Schatzberg AF (2004). Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. J Psychiatr Res 38: 27-35.
11. Gesing A, Bilang-Bleuel A, Droste SK, Linthorst AC, Holsboer F, Reul JM (2001). Psychological stress increases hippocampal mineralocorticoid receptor levels: involvement of corticotropin-releasing hormone. J Neurosci 21: 4822-4829.
12. Hamilton M (1980). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 49-65.
13. Hill SK, Keshavan MS, Thase ME, Sweeney JA (2004). Neuropsyhcological dysfunction in antipsychotic-naïve first-episode unipolar psychotic depression. Am J Psychiatry 161: 996-1003.
14. Johnson J, Horvath E, Weissman MM (1991). The validity of major depression with psychotic features based on a community sample. Arch Gen Psychiatry 48: 1075-1081.
15. Kalman BA, Spencer RL (2002). Rapid corticosteroid-dependent regulation of mineralocorticoid receptor protein expression in rat brain. Endocrinology 143: 4184-4195.
16. Karssen AM, Meijer OC, van der Sandt IC, De Boer AG, De Lange EC, De Kloet ER (2002). The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol 175: 251-260.
17. Kathol RG, Anton R, Noyes R, Gehris T (1989). Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder. Biol Psychiatry 25: 873-878.
18. Lupien SJ, Gillin CJ, Hauger RL (1999). Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans. Behav Neurosci 113: 420-430.
19. Mahajan DK, London SN (1997). Mifepristone (RU486): a review. Fertil Steril 68: 967-976.
20. Nelson JC, Davis JM (1997). DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 154: 1497-1503.
21. Newcomer JW, Selke G, Melson AK, Hershey T, Craft S, Richards K et al (1999). Decreased memory performance in healthy humans induced by stress-level cortisol treatment. Arch Gen Psychiatry 56: 527-533.
22. Ohayon MM, Schatzberg AF (2002). Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry 159: 1855-1861.
23. Oitzl MS, van Haarst AD, Sutanto W, de Kloet ER (1995). Corticosterone, brain mineralocorticoid receptors (MRs) and the activity of the hypothalamic-pituitary-adrenal (HPA) axis: the Lewis rat as an example of increased central MR capacity and a hyporesponsive HPA axis. Psychoneuroendocrinology 20: 655-675.
24. Otte C, Jahn H, Yassouridis A, Arlt J, Stober N, Maass P et al (2003). The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. Life Sci 73: 1835-1845.
25. Overall JE, Gorham DE (1961). The brief psychiatric rating scale. Psychol Rep 10: 799-812.
26. Oxenkrug GF, Pomara N, McIntyre IM, Branconnier RJ, Stanley M, Gershon S (1983). Aging and cortisol resistance to suppression by dexamethasone: a positive correlation. Psychiatry Res 10: 125-130.
27. Pariante CM, Kim RB, Makoff A, Kerwin RW (2003). Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membraine steroid transporters. Br J Pharmacol 134: 1111-1118.
28. Pariante CM, Makoff A, Lovestone S, Feroli S, Heyden A, Miller AH et al (2001). Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membraine steroid transporters. Br J Pharmacol 134: 1335-1343.
29. Rosenbaum AH, Schatzberg AF, MacLaughlin RA, Snyder K, Jiang NS, Ilstrup D et al (1984). The dexamethasone suppression test in normal control subjects: comparison of two assays and effect of age. Am J Psychiatry 141: 1550-1555.
30. Rothschild AJ (2003). Challenges in the treatment of depression with psychotic features. Biol Psychiatry 53: 680-690.
31. Sachar EJ, Hellman L, Roffwarg HP, Halpern FS, Fukushima DK, Gallagher TF (1973). Disrupted 24-h patterns of cortisol secretion in psychotic depression. Arch Gen Psychiatry 28: 19-24.
32. Schatzberg AF, Posener JA, DeBattista C, Kalehzan BM, Rothschild AJ, Shear PK (2000). Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Am J Psychiatry 157: 1095-1100.
33. Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED, Cole JO (1985). A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 19: 57-64.
34. Simpson GM, El Sheshai A, Loza N, Kingsbury SJ, Fayek M, Fawzy W (2005). An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J Clin Psychiatry 66: 598-602.
35. Spencer RL, Kim PJ, Kalman BA, Cole MA (1998). Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity. Endocrinology 139: 2718-2726.
36. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF et al (1985). The pharmacological treatment of delusional depression. Am J Psychiatry 142: 430-436.
37. Spitz IM, Bardin CW (1993). Mifepristone (RU 486) - a modulator of progestin and glucocorticoid action. N Engl J Med 329: 404-412.
38. Trapp T, Holsboer F (1996). Heterodimerization between mineralocorticoid and glucocorticoid receptors increases the functional diversity of corticosteroid action. Trends Pharmacol Sci 17: 145-149.
39. Vythilingam M, Chen J, Bremner JD, Mazure CM, Maciejewski PK, Nelson JC (2003). Psychotic depression and mortality. Am J Psychiatry 160: 574-576.
40. Wiedemann K, Lauer C, Loycke A, Pollmacher T, Durst P, Macher JP et al (1992). Antiglucocorticoid treatment disrupts endocrine cycle and nocturnal sleep pattern. Eur Arch Psychiatry Clin Neurosci 241: 372-375.
41. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. (2004). Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU486) in bipolar disorder. Neuropsychopharmacology 29: 1538-1545.
42. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H (2003). Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry 60: 24-28.